Autentificare
NeuroPsy InfoHubÎnțelege · Sprijin · ProgresCere sprijin

Informație de încredere. Sprijin real.

Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.

Începe gratuitSunt părinteSunt specialist
Spațiu publicitar disponibil — bannerul mare de susSpațiu publicitar disponibil — bannerul mare de sus

Explorează temele

Caută tot →

Sănătate mintală și neurodezvoltare

AutismSpectrul autist și particularitățile asociate.496 de articole
ADHDAtenție, impulsivitate și hiperactivitate.396 de articole
Sindrom DownDezvoltare și sprijin pentru sindromul Down.330 de articole
AnxietateÎngrijorare excesivă, tensiune, atacuri de panică.75 de articole
DepresieTristețe persistentă, lipsa energiei și a motivației.110 articole
AdicțiiDependențe de substanțe și comportamentale.137 de articole

Afecțiuni neurologice

DemențeBoala Alzheimer și alte forme de demență.74 de articole
AVC și AITAccident vascular cerebral și recuperare, la orice vârstă.67 de articole
Leziuni medulareLeziuni medulare, paraplegie și tetraplegie.59 de articole
EpilepsieCrize epileptice și managementul lor.128 de articole
ParkinsonBoala Parkinson și tulburări de mișcare.65 de articole
Scleroză multiplăScleroza multiplă și viața cu aceasta.72 de articole
Traumatisme cranio-cerebraleTraumatisme cranio-cerebrale și recuperare.88 de articole

Evaluare Psihologica

Ca stim de unde pornim

Programeaza o evaluare →

Articole și ghiduri recomandate

PublicToțiPentru oricineSpecialiști
VârstăToate vârsteleCopiiTineriAdulțiVârstnici
StudiuDepresieÎncredere bună16.06.2026

Anhedonia in Depressive Disorder and Schizophrenia: Causes, Diagnosis, and Treatment Overview

Anhedonia, the inability to experience pleasure, is a challenging symptom in major depressive disorder and schizophrenia involving dopaminergic system dysfunction. Treatment approaches include combination pharmacotherapy (glutamatergic agents, KOR antagonists, KCNQ activators), neurostimulation, and psychotherapy, with accurate component identification and reward system understanding being key to selecting effective interventions.

StudiuDepresieÎncredere bună16.06.2026

Psychological and Psychiatric Consequences of Prolonged Fasting: A Narrative Synthesis of Neurobiological and Clinical Evidence

This narrative synthesis systematically examines peer-reviewed research on how prolonged and intermittent fasting affect mood, cognition, stress physiology, and psychiatric symptoms, covering both secular and religious fasting practices from 2010-2025. The review evaluates clinical trials and observational studies while critically assessing study quality and vulnerability factors, acknowledging that psychoneurobiological psychiatric consequences of fasting remain incompletely characterized despite documented metabolic benefits.

StudiuDepresieÎncredere bună16.06.2026

Elevated Matrix Metalloproteinase 9 (MMP-9) Levels in Depressed Individuals with Recent Suicide Attempts

This study measured blood MMP-9 levels in 186 depressed hospital patients (92 with recent suicide attempts, 94 without) and 79 non-psychiatric controls, finding significantly elevated MMP-9 in the recent attempt group compared to both other groups. Results suggest MMP-9 may be a biological marker associated with suicide risk in major depressive disorder.

StudiuDepresieÎncredere bună16.06.2026

Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder

This review evaluates psilocybin's therapeutic potential for major depressive disorder by analyzing clinical studies from 2014-2024, examining its efficacy, safety, and mechanisms of action through serotonin receptor activity and neuroplasticity enhancement. The research highlights promising rapid and sustained symptom relief but emphasizes the need for larger studies, regulatory reform, and long-term safety data to fully establish psilocybin-assisted therapy as a viable treatment option.

StudiuDepresieÎncredere bună16.06.2026

Psychiatric effects of GLP-1 receptor agonists: A systematic review of emerging evidence

This systematic review evaluates the association between GLP-1 receptor agonists (medications used for diabetes and weight loss) and psychiatric manifestations including depression, suicidality, eating disorders, and substance use disorders. Evidence suggests modest antidepressant effects and potential therapeutic benefit in reward-regulation disorders, though concerns about suicidality remain unresolved and research is limited by small sample sizes and underrepresentation of people with psychiatric comorbidities.